Portfoliotracker

Apnimed, Inc.

APMD · NASDAQGS · Healthcare Biotechnology 66/100 B

16,28 $
▼ −0,64 (−3,78 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:32
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score66 / 100 Market cap527 mil. $ P/E2,2 Forward P/E-4,3 P/S4,6 P/B– EV/EBITDA11,1 Dividend yield– FCF yield-13,34 % EPS7,22 $ Net margin142,1 % Return on equity– Beta– Debt / equity1,30
52-week range 13,88 to 35,29
3-month average volume0,5 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Employees
81
Country
United States
Fiscal year end
31. 12.
Data since
31. 7. 2026

Explore further

Similar companies SCTXKLRABRVECOAGLTGO

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account